A Phase 3 study of Odiparcil as a monotherapy and in combination with enzyme replacement therapy for the treatment of adult and pediatric patients with MPS VI
Latest Information Update: 10 Jul 2020
At a glance
- Drugs Odiparcil (Primary) ; Enzyme replacements
- Indications Mucopolysaccharidosis VI
- Focus Therapeutic Use
- Sponsors Inventiva Pharma
- 10 Jul 2020 New trial record